Cystic fibrosis (CF) is caused by loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes an adenosine triphosphate (ATP)-gated chloride and bicarbonate channel expressed on airway, intestinal, pancreatic ductal, and other epithelial surfaces. Modulator therapies do not repair the underlying genetic mutation; instead they rescue the defective CFTR protein at the protein-folding, trafficking, or gating level, restoring partial or near-normal channel function in patients who carry at least one mutation amenable to that mechanism.
The cystic fibrosis transmembrane conductance regulator (CFTR) is a member of the ATP-binding cassette (ABC) transporter superfamily and functions as a cAMP (cyclic adenosine monophosphate)-activated chloride channel. It is composed of two membrane-spanning domains (MSDs) that form the channel pore, two nucleotide-binding domains (NBDs) that bind and hydrolyze ATP to gate the channel open and closed, and a regulatory (R) domain whose phosphorylation by protein kinase A (PKA) is required for channel activation. In normal airway epithelium, apical CFTR activity drives chloride and water secretion into the airway lumen, maintaining the periciliary liquid layer that allows mucociliary clearance. Loss of CFTR function produces dehydrated, viscous airway secretions that impair ciliary clearance, leading to chronic bacterial colonization, bronchiectasis (permanent airway dilation from repeated infection and inflammation), and progressive obstructive lung disease that accounts for greater than 80 percent of CF-related mortality.1
CF mutations are grouped into six classes based on the molecular mechanism of CFTR dysfunction, a taxonomy that directly predicts modulator eligibility. Class I mutations (nonsense and frameshift mutations, including G542X and W1282X) produce premature stop codons that result in absent or severely truncated, nonfunctional CFTR protein through nonsense-mediated mRNA decay (NMD); these are the most difficult to target pharmacologically. Class II mutations (the most common, including the phenylalanine-508 deletion, abbreviated F508del, present on at least one allele in approximately 85 to 90 percent of CF patients) produce misfolded CFTR protein that is recognized by the endoplasmic reticulum (ER) quality control machinery and degraded before reaching the apical membrane; F508del CFTR additionally has a gating defect even in the small fraction that does reach the cell surface.2
Class III mutations (gating mutations, including G551D (glycine-to-aspartate substitution at position 551), present in approximately 4 to 5 percent of CF patients) produce CFTR that traffics normally to the apical membrane but cannot open appropriately in response to adenosine triphosphate (ATP) binding. Class IV mutations produce CFTR that reaches the membrane but has reduced conductance through the channel pore. Class V mutations reduce the amount of normal CFTR produced. Class VI mutations produce unstable surface CFTR with accelerated turnover.
The pharmacological distinction between CFTR potentiators and CFTR correctors maps directly onto this mutation taxonomy. A potentiator is a small molecule that binds to CFTR already present at the apical cell surface and increases the probability that the channel gate is open, enhancing chloride conductance through channels that are present but functionally impaired. Potentiators are therefore effective for class III (gating) mutations, where the problem is a channel that cannot open, and provide partial benefit for class IV mutations. They also partially rescue the gating defect in F508del CFTR that reaches the membrane. A corrector is a small molecule that stabilizes misfolded CFTR protein in the endoplasmic reticulum, improving its folding, reducing ER-associated degradation (ERAD), and allowing more CFTR to traffic to the apical membrane. Correctors address class II processing mutations; F508del is the most prevalent of these and the primary target of approved corrector therapy. Because F508del has both a processing defect (corrected by correctors) and a gating defect (corrected by potentiators), F508del-targeted therapy requires both corrector and potentiator activity, which is why all approved regimens for F508del include ivacaftor as a potentiator component alongside one or two correctors.3
Before prescribing any CFTR modulator, confirm the patient's CFTR genotype at both alleles. Modulators are approved only for patients carrying specific mutations or mutation classes. F508del is by far the most common actionable mutation and is the basis for the triple combination elexacaftor-tezacaftor-ivacaftor (ETI) regimen. Patients with two class I mutations and no amenable allele currently have no approved modulator option and should be directed to clinical trials and best supportive care.
Ivacaftor was the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator approved and established proof of concept that small-molecule rescue of the defective CFTR protein could produce clinically meaningful improvements in lung function, sweat chloride concentration, and quality of life. Its mechanism is that of a channel potentiator: it binds to CFTR at the cell surface and increases the open probability of the channel gate without altering the amount of CFTR protein present.
Ivacaftor binds to cystic fibrosis transmembrane conductance regulator (CFTR) at a site within or near the transmembrane domains and increases the open probability (Po) of the channel gate, allowing chloride to flow through channels that are already at the apical membrane but fail to open normally. This mechanism is independent of the upstream folding and trafficking steps addressed by correctors. In the context of G551D (a class III gating mutation) CFTR, where the gating defect is the dominant dysfunction, ivacaftor monotherapy is highly effective. The pivotal STRIVE (Study of VX-770 (ivacaftor) in Subjects with Cystic Fibrosis and the G551D-CFTR (G551D cystic fibrosis transmembrane conductance regulator) Mutation) trial enrolled 161 patients aged 12 and older with at least one G551D allele and demonstrated a mean improvement in forced expiratory volume in one second as percent predicted (FEV1% predicted) of 10.6 percentage points compared with placebo over 48 weeks, a reduction in sweat chloride concentration of approximately 48 mmol/L, and significant improvement in the cystic fibrosis (CF) questionnaire–revised (CFQ-R) respiratory domain score.4 This magnitude of FEV1 improvement had never been seen with any prior CF therapy and established CFTR modulation as a paradigm shift in CF care.
The initial approval of ivacaftor monotherapy was for G551D only, but subsequent clinical trials and regulatory submissions extended its indication to a growing list of gating and residual function mutations. Ivacaftor monotherapy is now approved in the United States for patients aged 4 months and older who have at least one of 97 mutations in the CFTR gene that are responsive to ivacaftor based on in vitro or clinical data, encompassing most gating mutations (class III) and many residual function mutations (class IV and V). The breadth of this mutation coverage reflects the mechanistic rationale: any CFTR that reaches the apical membrane with a gating or conductance defect is potentially rescuable by potentiation, regardless of the specific mutation causing that defect. Patients with two class I mutations and no functional CFTR protein at the surface do not benefit from potentiators alone because there is no channel to potentiate.5
Ivacaftor is metabolized primarily by cytochrome P450 isoform CYP3A4 (cytochrome P450 family 3 subfamily A member 4), a pharmacokinetic consideration of the highest clinical importance that governs all modulator combination regimens. Strong CYP3A4 inhibitors, including azole antifungal agents (itraconazole, voriconazole, posaconazole, fluconazole, ketoconazole) and certain macrolides, increase ivacaftor plasma concentrations substantially; co-administration requires dose reduction of ivacaftor to every-other-day dosing per labeling, or avoidance of the combination. Strong CYP3A4 inducers, including rifampin and some anticonvulsants such as carbamazepine and phenytoin, markedly reduce ivacaftor exposure, potentially below therapeutic concentrations; their concurrent use with any ivacaftor-containing regimen should be avoided. This CYP3A4 interaction is particularly clinically relevant because CF patients frequently require antifungal therapy for Aspergillus colonization and broad-spectrum antibiotics for pulmonary exacerbations, creating repeated drug interaction scenarios that require active management at each prescribing encounter.6
Patients with CF who require treatment for Aspergillus fumigatus colonization or allergic bronchopulmonary aspergillosis (ABPA) with itraconazole, voriconazole, or posaconazole face a significant drug interaction: all three are strong CYP3A4 inhibitors that can increase ivacaftor exposure several-fold. Per prescribing labeling, reduce ivacaftor-containing regimen dosing to every other day when co-prescribing a strong CYP3A4 inhibitor. Document this adjustment in every encounter; the interaction recurs whenever antifungal therapy is initiated or changed.
Cystic fibrosis transmembrane conductance regulator (CFTR) correctors target the upstream processing defect in class II mutations: they stabilize the misfolded CFTR protein in the endoplasmic reticulum, reduce degradation by the proteasomal quality control machinery, and increase the amount of CFTR that successfully traffics to the apical cell membrane. Because the phenylalanine-508 deletion CFTR protein retains a gating defect even after its processing defect is corrected, correctors must always be combined with ivacaftor in F508del-targeted therapy.
Lumacaftor is the first-generation CFTR corrector and works by binding directly to F508del CFTR in the endoplasmic reticulum (ER), stabilizing the protein in a conformation that reduces recognition by the ER quality control machinery, specifically the Hsp70/Hsp90 chaperone and co-chaperone complex, and decreasing ER-associated degradation (ERAD) so that more F508del CFTR can complete folding and traffic to the Golgi and then to the apical membrane. Lumacaftor is approved only in combination with ivacaftor as the fixed-dose combination product (Orkambi) for patients aged 2 years and older who are homozygous for F508del (two copies of the F508del mutation). The pivotal TRAFFIC (Study of Lumacaftor in Combination with Ivacaftor) and TRANSPORT (Study of Lumacaftor and Ivacaftor Combination Treatment) trials (Wainwright 2015) randomized a combined 1108 patients with two copies of F508del and demonstrated improvements in forced expiratory volume in one second as percent predicted (FEV1% predicted) of approximately 2.6 to 4.0 percentage points compared with placebo and reductions in the rate of pulmonary exacerbations by approximately 30 to 39 percent.7 These improvements were more modest than those seen with ivacaftor in G551D (class III gating mutation) patients, reflecting the incomplete rescue of F508del by first-generation corrector therapy.
Lumacaftor presents a clinically significant and counterintuitive drug interaction: it is a strong inducer of cytochrome P450 isoform CYP3A4 (the primary hepatic enzyme responsible for ivacaftor metabolism). When lumacaftor is co-administered with ivacaftor in the fixed combination product, lumacaftor induces CYP3A4 and markedly reduces ivacaftor plasma concentrations, partially attenuating the benefit of potentiation. This interaction explains in part the more modest clinical efficacy of lumacaftor-ivacaftor compared with later regimens, and it has important implications for other CYP3A4 substrate drugs taken by the patient, whose concentrations may be substantially reduced by lumacaftor induction. Lumacaftor-ivacaftor is also associated with chest tightness and respiratory adverse events, particularly in patients with FEV1% predicted below 40 percent, which may limit tolerability in severe disease, and with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST), collectively liver transaminases, requiring liver function monitoring.
Tezacaftor is the second-generation CFTR corrector with a binding site on CFTR distinct from lumacaftor and a more favorable pharmacokinetic profile. Unlike lumacaftor, tezacaftor does not induce CYP3A4, eliminating the paradoxical self-attenuating interaction seen with lumacaftor-ivacaftor. The fixed combination of tezacaftor plus ivacaftor (Symdeko) was studied in the EVOLENT (Efficacy and Safety Study of Tezacaftor in Combination with Ivacaftor in Subjects with Cystic Fibrosis) trial (Taylor-Cousar 2017) and demonstrated improvements in FEV1% predicted of approximately 4.0 percentage points in F508del homozygotes and approximately 6.8 percentage points in patients with one F508del allele and one residual function allele, with a more favorable respiratory tolerability profile than lumacaftor-ivacaftor.8 Tezacaftor-ivacaftor is approved for patients aged 6 years and older who are homozygous for F508del or who have at least one copy of F508del plus a residual function mutation. The mechanism of combined corrector-potentiator action is additive: tezacaftor increases the amount of F508del CFTR reaching the membrane, while ivacaftor increases the open probability of the F508del CFTR that does reach the membrane, together producing greater chloride transport than either agent alone.
Lumacaftor is a strong inducer of CYP3A4 and significantly reduces plasma concentrations of ivacaftor and of all other CYP3A4 substrate drugs taken concurrently, including hormonal contraceptives (efficacy substantially reduced; alternative non-hormonal contraception required), immunosuppressants such as tacrolimus and cyclosporine (monitor levels closely), and anticoagulants. Tezacaftor-ivacaftor and the elexacaftor-tezacaftor-ivacaftor triple combination do not share this induction problem, which is one clinical reason to prefer the newer regimens when they are available and indicated.
The approval of elexacaftor-tezacaftor-ivacaftor (ETI) (marketed as Trikafta in the United States) in 2019 represented the most significant advance in cystic fibrosis (CF) pharmacotherapy since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. By combining two structurally distinct correctors targeting different binding sites on the phenylalanine-508 deletion CFTR protein with the ivacaftor potentiator, ETI produces substantially greater F508del rescue than any prior modulator regimen and has transformed the disease trajectory for the approximately 90 percent of CF patients who carry at least one F508del allele.
Elexacaftor is a next-generation CFTR corrector that binds to a site on F508del CFTR distinct from the tezacaftor binding site. When elexacaftor and tezacaftor are used together, they engage two different regions of the misfolded F508del CFTR protein simultaneously, producing a cooperative stabilization that is substantially greater than either corrector alone. This dual-corrector synergy, combined with ivacaftor potentiation of the corrected protein that reaches the apical membrane, constitutes the mechanistic basis of the triple combination's superior efficacy over the dual combination. The elexacaftor-tezacaftor-ivacaftor (ETI) regimen is taken as two tablets in the morning (containing elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg) and one tablet of ivacaftor 150 mg in the evening, a fixed schedule designed to maintain both corrector concentrations and ivacaftor concentrations throughout the 24-hour dosing cycle.9
The pivotal VX-445-102 (elexacaftor phase 3) trial (Middleton 2019) enrolled 403 patients aged 12 and older with one F508del allele and one minimal function allele (a mutation that produces no functional CFTR protein, such as a class I mutation) and demonstrated a mean improvement in forced expiratory volume in one second as percent predicted (FEV1% predicted) of 13.8 percentage points compared with placebo, a reduction in sweat chloride of 41.8 mmol/L, and significant improvements in the CF questionnaire-revised (CFQ-R) respiratory domain score.10 A parallel arm enrolled F508del homozygous patients and demonstrated a 10.0 percentage-point improvement in FEV1% predicted compared with the tezacaftor-ivacaftor comparator, confirming incremental benefit of the triple combination over the dual corrector-potentiator combination even in patients already on effective corrector therapy. The magnitude of these results, particularly the FEV1 gains in F508del heterozygotes with minimal function mutations who had no prior modulator option, established ETI as the standard of care for all patients who carry at least one F508del allele.
The clinical impact of ETI on CF disease course has been profound and is now reflected in real-world registry data that show reductions in hospitalization rates, pulmonary exacerbation frequency, and rates of lung transplant listing among ETI-treated patients compared with pre-ETI historical cohorts.11 Sweat chloride normalization, defined as a reduction below 60 mmol/L, is achieved in a substantial proportion of ETI-treated patients and has emerged as a biomarker of CFTR functional restoration. Long-term follow-up data from extension studies suggest durability of lung function benefit over multiple years of continuous treatment. The introduction of ETI has also raised questions about whether established lung disease manifestations, including bronchiectasis and chronic Pseudomonas aeruginosa colonization, can be reversed or merely stabilized, and current evidence suggests that structural lung damage that predates ETI initiation does not regress significantly, underscoring the benefit of early initiation before irreversible airway remodeling occurs.
ETI shares the cytochrome P450 isoform CYP3A4 (CYP3A4) metabolic pathway of all ivacaftor-containing regimens, though elexacaftor and tezacaftor do not induce CYP3A4, as lumacaftor did. The same dose adjustment rules apply to strong CYP3A4 inhibitors: every-other-day dosing of the morning dual-corrector tablet and the evening ivacaftor tablet when a strong inhibitor is co-prescribed. Hepatotoxicity with elevated liver transaminases (ALT and AST) is an adverse effect that occurs in a subset of patients; liver function tests (LFTs) should be measured before starting ETI, at 3 months, and then annually, with more frequent monitoring if elevations occur. ETI is approved for patients aged 2 years and older in the United States, and the labeled age threshold has progressively lowered as pediatric trial data have become available, reflecting the rationale for initiating modulator therapy as early in life as possible to prevent the cumulative airway damage that drives long-term morbidity.
Elexacaftor-tezacaftor-ivacaftor (ETI) is approved for CF patients aged 2 years and older who have at least one F508del allele. This includes: (1) F508del homozygotes (two copies); (2) F508del compound heterozygotes who have one F508del allele and one minimal function allele (class I mutations); and (3) F508del compound heterozygotes with one F508del and one residual function allele. Patients with two non-F508del class I mutations and no F508del allele do not qualify. Confirm genotype at both alleles before prescribing. Approximately 85 to 90 percent of CF patients carry at least one F508del allele and are therefore eligible.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy has dramatically altered the trajectory of cystic fibrosis (CF), but it has not eliminated the need for ongoing monitoring, adjunctive airway clearance therapies, or management of extrapulmonary CF manifestations. The clinician's role has shifted from managing progressive decline to sustaining the gains of modulator therapy while vigilantly addressing drug interactions, monitoring toxicity, and managing persistent complications that predate or persist through modulator use.
Hepatotoxicity is the principal laboratory monitoring concern for all CFTR modulators. All approved regimens containing ivacaftor, tezacaftor, or elexacaftor carry a risk of transaminase elevations. For elexacaftor-tezacaftor-ivacaftor (ETI), liver function tests (LFTs), specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST), should be measured before initiating therapy, at 3 months after initiation, and then annually in stable patients. If ALT or AST exceeds five times the upper limit of normal (ULN) without symptoms, or three times the ULN with symptoms of liver toxicity (jaundice, right upper quadrant pain, nausea), ETI should be interrupted and liver function reassessed. Resolution and rechallenging at a lower dose or with more frequent monitoring is sometimes feasible under specialist guidance; permanent discontinuation may be required in severe cases. Patients with pre-existing liver disease or CF-related liver disease, which itself affects approximately 30 percent of CF patients to some degree, require more frequent baseline assessment and closer monitoring throughout therapy.12
The cytochrome P450 isoform CYP3A4 (CYP3A4) drug interaction framework requires active management at every clinical encounter for CF patients on modulator therapy. The key scenarios are: strong CYP3A4 inhibitors (azole antifungals, certain macrolides) requiring every-other-day dosing of the ETI regimen; strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) which should be avoided with any ivacaftor-containing regimen because they reduce modulator plasma concentrations below effective levels. A practical challenge specific to CF is that rifampin, a strong inducer, is occasionally used for nontuberculous mycobacteria (NTM) lung disease in CF patients; concurrent use with any CFTR modulator is generally contraindicated, and antibiotic selection for NTM infection must account for this restriction. When azole antifungals are unavoidable, dose-adjust the modulator regimen per labeling and document the adjustment in the patient's record for continuity across encounters.
Despite the transformative efficacy of ETI, adjunctive airway clearance therapies and inhaled mucoactive agents remain clinically relevant for most patients, at least in the early years after ETI initiation. Inhaled hypertonic saline (7% sodium chloride) improves mucociliary clearance by drawing water onto the airway surface, hydrating the mucus layer and reducing viscosity. Dornase alfa (recombinant human DNase I) degrades extracellular deoxyribonucleic acid (DNA) released from neutrophils in infected CF airways, reducing mucus viscosity and improving sputum rheology and clearance. Both agents were established before the modulator era and retain their role in patients with established bronchiectasis and chronic airway secretions even after ETI initiation, though the degree of ongoing benefit relative to pre-ETI levels requires individualized reassessment. Physical airway clearance techniques, including positive expiratory pressure (PEP) devices and high-frequency chest wall oscillation (HFCWO) vests, continue as part of the management plan for most patients with significant lung disease.13
CF-related diabetes (CFRD) affects approximately 20 percent of adolescents and 40 to 50 percent of adults with CF and is caused by destruction of pancreatic islet cells by progressive pancreatic exocrine fibrosis, compounded by insulin resistance during pulmonary exacerbations. CFRD is distinct from type 1 and type 2 diabetes mellitus in its pathophysiology and clinical behavior: it typically presents with relative insulin deficiency without ketoacidosis, often begins as postprandial hyperglycemia, and is best diagnosed by oral glucose tolerance testing (OGTT) rather than hemoglobin A1c (HbA1c), which may be falsely low in CF patients due to increased red blood cell turnover. Insulin therapy is the preferred treatment for CFRD, as it directly addresses the underlying insulin deficiency and may have anabolic benefits in a patient population prone to malnutrition. ETI therapy appears to slow the progression of CFRD in some patients by improving pancreatic ductal function, though the impact on established CFRD requiring insulin is more limited. CF-related bone disease, manifesting as reduced bone mineral density (BMD) and increased fracture risk, affects the majority of adult CF patients and requires calcium supplementation, fat-soluble vitamin supplementation (vitamins A, D, E, and K), and periodic dual-energy X-ray absorptiometry (DEXA) scanning, with bisphosphonate therapy reserved for patients with low BMD and fracture history.12
Approximately 10 to 15 percent of CF patients carry two class I mutations with no F508del allele and have no currently approved modulator option. Management for these patients relies on: aggressive airway clearance, inhaled dornase alfa and hypertonic saline, early and aggressive antibiotic treatment of pulmonary exacerbations, nutritional support and pancreatic enzyme replacement, and lung transplant evaluation when FEV1% predicted falls below 30 percent or decline is rapid. Clinical trial enrollment should be actively discussed with all modulator-ineligible patients, as multiple investigational approaches including read-through agents for nonsense mutations and next-generation modulators are in active development.
Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352(19):1992–2001.
doi:10.1056/NEJMra043184Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73(7):1251–1254.
doi:10.1016/0092-8674(93)90353-RBoyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2013;1(2):158–163.
doi:10.1016/S2213-2600(12)70057-7Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672.
doi:10.1056/NEJMoa1105185Van Goor F, Hadida S, Grootenhuis PDJ, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106(44):18825–18830.
doi:10.1073/pnas.0904709106Lommatzsch ST, Taylor-Cousar JL. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy. Ther Adv Respir Dis. 2019;13:1753466619844424.
doi:10.1177/1753466619844424Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(3):220–231.
doi:10.1056/NEJMoa1409547Taylor-Cousar JL, Munck A, McKone EF, et al. Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med. 2017;377(21):2013–2023.
doi:10.1056/NEJMoa1709846Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–1948.
doi:10.1016/S0140-6736(19)32597-8Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–1819.
doi:10.1056/NEJMoa1908639Nichols DP, Happoldt CL, Bratcher PE, et al. Impact of elexacaftor-tezacaftor-ivacaftor on the clinical course of cystic fibrosis: 1 year post-approval outcome tracking. J Cyst Fibros. 2022;21(2):228–235.
doi:10.1016/j.jcf.2021.10.005Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626–1631.
doi:10.2337/dc09-0586Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–240.
doi:10.1056/NEJMoa043900